Conversely, the tyrosine kinase inhibitor sorafenib demonstrated significant decreases in tumor volume in Dhh-Cre;Nf1flox/flox GEMM neurofibromas, but PK parameters did not align with human patients, and children with NF1-associated plexiform neurofibromas did not tolerate sorafenib at doses significantly lower than those of non-NF1 children with other advanced cancers [91,92]. The gene discussed is NF1; the disease is neoplasm.